M&A / Deals AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid Pharmaceutical TechnologyAbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.M&A / DealsPain & AnaesthesiaRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries. M&A / DealsPain & AnaesthesiaRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: AbbVie enters world of pain in up to $715M deal with China’s Haisco Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
